The company’s intellectual property portfolio consists of several approved patents and patent applications based on unique chemical compounds in the form of aptamer-based drug candidates and their applications. The drug candidates are protected by the strongest form of patent protection in the pharmaceutical industry, entailing that the unique RNA aptamers hold product patent protection.
For recently acquired patentable technology, Aptahem strategically plans to apply for patents in countries that are expected to become key markets for the company in the future. Currently, the following markets are being considered: Europe, the US, Canada and certain important markets in Asia and the rest of the world. The company intends to apply for additional patents in the event that the Board considers that the company should strengthen the intellectual property portfolio further.
Region | Application number | Application date | Expiration date | Status |
---|---|---|---|---|
Europe | 09708523.7 | 2009-02-05 | 2029-02-05 | Approved |
USA | 12/866413 | 2009-02-05 | 2029-02-05 | Approved |
Canada | 2714121 | 2009-02-05 | 2029-02-05 | Approved |
China | 20098011646.4 | 2009-02-05 | 2029-02-05 | Approved |
India | 6250/DELNP/2010 | 2009-02-05 | 2029-02-05 | Ongoing |
Region | Application number | Application date | Expiration date | Status |
---|---|---|---|---|
Brazil | 11 2020 005995 1 | 2017-10-03 | 2037-10-03 | Ongoing |
Canada | 3073364 | 2017-10-03 | 2037-10-03 | Ongoing |
China | 2018800643106 | 2017-10-03 | 2037-10-03 | Ongoing |
Europe | 18783424.7 | 2017-10-03 | 2037-10-03 | Ongoing |
Israel | 273759 | 2017-10-03 | 2037-10-03 | Ongoing |
Japan | 2020-519806 | 2017-10-03 | 2037-10-03 | Ongoing |
South Korea | 10-2020-7007266 | 2017-10-03 | 2037-10-03 | Ongoing |
USA | 16/652,926 | 2017-10-03 | 2037-10-03 | Ongoing |